University of Pittsburgh 
GRADUATE SCHOOL OF PUBLIC HEALTH 
Department of Industrial Environmental Health Sciences 
October 1, 1979 
Dr. Donald S. Fredrickson 
National Institutes of Health 
5600 Fishers Lane 
Rockville, MD. 
Dear Dr. Fredrickson: 
I write to support Dr. Goldstein's letter and to add some 
comments of my own. The committee has, as you know, a majority of 
members who are pursuing careers in Recombinant DNA research. I have 
no reason to believe that any of them are presently consulting for 
industrial companies who have now or may in the future request exempt- 
ions from the current guidelines but obviously the potential for such 
conflict exists. I feel that all members should be at least voluntarily 
asked to agree not to consult, now or for two years after leaving the 
committee, for companies engaged in Recombinant DNA work. 
I am also deeply concerned with the decisions taken by the 
committee on the applications of Eli Lilly and Genentech. 
One member of the committee is apparently going to visit the plants 
at intervals. This is very close to the committee becoming involved in 
inspection procedures and licensing, an area where we have no expertise, 
and no charge. 
I also asked for the matter of OSHA regulations and coverage of 
laboratories and industrial facilities to be discussed at a meeting of 
the Interagency Liaison committee. The split vote was decided by the 
Chairperson and my motion was lost. I would again like to request that 
such a meeting be held and for the meeting to include sone imput from 
representation of labor and involved industry. 
Yours : 
David K. Parkinson, M.D 
DKP/mh 
[ 336 ] 
PITTSBURGH, PA. 15261 
